Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$17.69 -0.4%	$18.18	$16.10 ▼ $42.47	$2.23B	0.68	2.35 million shs	2.09 million shs
DNTH Dianthus Therapeutics	$16.85 -3.4%	$19.25	$13.37 ▼ $32.27	$560.87M	1.36	278,218 shs	409,038 shs
GMTX Gemini Therapeutics	$50.09 +0.1%	$46.96	$1.16 ▼ $14.10	$2.17B	-0.12	189,291 shs	321,187 shs
NAMS NewAmsterdam Pharma	$17.96 -1.3%	$18.51	$14.06 ▼ $27.29	$2.04B	-0.03	697,413 shs	1.01 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-0.39%	-6.05%	+1.55%	-26.72%	-55.85%
DNTH Dianthus Therapeutics	-3.38%	-7.97%	-10.13%	-13.55%	-32.27%
GMTX Gemini Therapeutics	0.00%	-4.97%	+0.02%	-4.12%	+15.04%
NAMS NewAmsterdam Pharma	-1.32%	-11.13%	-2.97%	-24.76%	+4.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.6977 of 5 stars	4.3	3.0	0.0	4.4	3.3	2.5	0.6
DNTH Dianthus Therapeutics	1.3806 of 5 stars	3.6	0.0	0.0	0.0	2.8	0.8	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.0053 of 5 stars	3.5	2.0	0.0	0.0	2.6	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	126.41% Upside
DNTH Dianthus Therapeutics	3.13	Buy	$53.00	214.54% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	138.80% Upside

Current Analyst Ratings Breakdown

Latest DNTH, GMTX, APLS, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	2.85	N/A	N/A	$1.84 per share	9.61
DNTH Dianthus Therapeutics	$6.24M	86.84	N/A	N/A	$11.91 per share	1.41
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
NAMS NewAmsterdam Pharma	$45.56M	44.26	N/A	N/A	$8.20 per share	2.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$2.88	N/A	N/A	N/A	-1,544.23%	-29.26%	-27.87%	8/6/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)

Latest DNTH, GMTX, APLS, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
DNTH Dianthus Therapeutics	N/A	15.98	15.99
GMTX Gemini Therapeutics	N/A	71.49	71.49
NAMS NewAmsterdam Pharma	N/A	19.98	19.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
DNTH Dianthus Therapeutics	47.53%
GMTX Gemini Therapeutics	75.42%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
DNTH Dianthus Therapeutics	8.15%
GMTX Gemini Therapeutics	12.90%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	29.54 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable

DNTH, GMTX, APLS, and NAMS Headlines

Recent News About These Companies

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up - Time to Buy?

June 20 at 11:55 AM | marketbeat.com

James N. Topper Acquires 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 19 at 7:42 AM | insidertrades.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Rating of "Buy" by Analysts

June 19 at 4:43 AM | marketbeat.com

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug

June 18 at 7:04 PM | investing.com

James N. Topper Purchases 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 18 at 6:21 PM | marketbeat.com

Insider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 100,000 Shares of Stock

June 18 at 5:56 PM | marketbeat.com

Citigroup Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)

June 18 at 2:17 AM | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Analysts at Citigroup

June 17, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Needham & Company LLC

June 15, 2025 | americanbankingnews.com

Dr. Reddy's Laboratories (NYSE:RDY) versus NewAmsterdam Pharma (NASDAQ:NAMS) Critical Review

June 14, 2025 | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Handelsbanken Fonder AB

June 13, 2025 | marketbeat.com

5NAMS : What Analysts Are Saying About NewAmsterdam Pharma...

June 12, 2025 | benzinga.com

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities

June 12, 2025 | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Given Buy Rating at Needham & Company LLC

June 12, 2025 | marketbeat.com

Stifel Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation

June 11, 2025 | msn.com

NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel

June 11, 2025 | insidermonkey.com

NewAmsterdam Pharma Rings the Closing Bell

June 11, 2025 | nasdaq.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.4% - Should You Sell?

June 11, 2025 | marketbeat.com

NewAmsterdam Pharma Schedules R&D Day for June 2025

June 11, 2025 | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Forecasts NAMS FY2026 Earnings

June 11, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH, GMTX, APLS, and NAMS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$17.69 -0.07 (-0.39%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$17.68 -0.01 (-0.06%)

As of 06/20/2025 06:15 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Dianthus Therapeutics NASDAQ:DNTH

$16.85 -0.59 (-3.38%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$16.82 -0.03 (-0.18%)

As of 06/20/2025 04:46 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Gemini Therapeutics NASDAQ:GMTX

$50.09 +0.04 (+0.08%)

As of 06/18/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$17.96 -0.24 (-1.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$18.15 +0.19 (+1.06%)

As of 06/20/2025 07:39 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time